MPMarina Galdino da Rocha Pitta

Marina Galdino da Rocha Pitta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marina Galdino da Rocha Pitta has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Thiazolidine derivative (LPSF/CR-35) modulates the production of IL-17A, IL-10, IL-4, TFN, CCL2 and CXCL8 in PBMC from systemic sclerosis patients

    by Andréa Tavares Dantas, Anderson Rodrigues de Almeida, Marina Ferraz Cordeiro, Priscilla Stela Santana de Oliveira, José Arion da Silva Moura, Michelly Cristiny Pereira, Moacyr Jesus Barreto de Melo Rêgo, Rafaela Silva Guimarães Gonçalves, Marina Galdino da Rocha Pitta, Angela Luzia Branco Pinto Duarte

    Background Systemic sclerosis (SSc) is an autoimmune disease characterized by vasculopathy, fibrosis, and dysregulation of the immune system. The therapeutic options available for SSc have limited efficacy, and there is a clear need for new pharmacological alternatives. Thiazolidinediones (TZD) are molecules that have therapeutic potential for SSc due to their pharmacological properties. In this study, we aimed to evaluate the immunomodulatory activity of a new TZD analogue (LPSF/CR-35) in peripheral blood mononuclear cells (PBMC) from SSc patients. Materials and methods PBMC response to LPSF/CR-35 (100µM) was examined from SSc patients (n = 19) and healthy control subjects (n = 8) following PBMC stimulation with anti-CD3/CD28. Cytokines (IFN-γ, TNF, IL-2, IL-4, IL-6, IL-10, and IL-17 A) and chemokines (CXCL8/IL-8, CCL5/RANTES, CXCL9/MIG, CCL2/MCP-1, and CXCL10/IP-10) levels were quantified in PBMC culture supernatants by cytometric bead array (CBA). In silico analyses were performed to evaluate the binding affinity of LPSF/CR-35 to peroxisome proliferator-activated receptor gamma (PPARγ). Results LPSF/CR-35 treatment significantly reduced the secretion of IL-17 A (p = 0.02), IL-10 (p = 0.001), IL-4 (p = 0.04), CCL2/MCP-1 (p = 0.003), and CXCL8/IL-8 (p = 0.03), while increasing TNF levels (p = 0.004) in PBMCs from SSc patients. Molecular docking predicted high binding affinity of both E (-9.987 kcal/mol) and Z (-9.992 kcal/mol) isomers of LPSF/CR-35 to PPARγ, supporting a possible PPARγ-dependent mechanism. Conclusions Our results indicate that LPSF/CR-35 modulates key cytokines and chemokines involved in SSc immunopathology, possibly through PPARγ activation. These findings support the potential of LPSF/CR-35 as an immunomodulatory agent in SSc. Further studies are needed to elucidate its effects on fibrosis and confirm its mechanism of action.

  • Open Access

    Novel Thiazolidinedione Derivatives as Potential ZIKV Antiviral Inhibitors

    by Isabella Luiza Ralph de Oliveira, José Arion da Silva Moura, Patricia Recordon-Pinson, Floriane Lagadec, Michelle Melgarejo da Rosa, Sayonara Maria Calado Gonçalves, Douglas Carvalho Francisco Viana, Paulo André Teixeira de Moraes Gomes, Marina Galdino da Rocha Pitta, Moacyr Jesus Barreto de Melo Rêgo, et al.

    Zika virus (ZIKV) remains a pressing global health concern due to its association with congenital Zika syndrome and the current lack of approved antiviral therapies. In this study, we evaluated the antiviral activity of three novel thiazolidinedione derivatives, GQ-402, GQ-396, and ZKC-10, against ZIKV in vitro and investigated their potential molecular targets through in silico analysis. GQ-402 exhibited the highest antiviral potency, with an IC50 of 15.7 µM, while ZKC-10 achieved the most substantial reduction in viral RNA levels, as determined by RT-qPCR. Molecular docking studies identified GQ-396 as the top-ranked inhibitor of the NS2B-NS3 protease and NS5 RNA-dependent RNA polymerase, suggesting distinct mechanisms of action among the compounds. These findings highlight the therapeutic potential of thiazolidinedione derivatives and underscore the need for further investigation to develop effective treatments for ZIKV infection.


  • Open Access

    Effects of Ginkgo Biloba on memory and cognitive function in patients with Alzheimer's disease

    by Pedro César de Souza, Thaynara Paula Warren Bezerra, Isabella Luiza Ralph de Oliveira, Maria Isabela Ferreira de Araujo, Yasmin Carvalho da Rocha Wanderley, Djair Marques Dias Júnior, Anaías Carine da Silva, Niedja Paula Vieira de Moraes, Paulo André Teixeira de Morais Gomes, Eduardo Augusto Vasconcelos de Freitas Ramalho, et al.

    This integrative review aims to synthesize scientific evidence on the effects of Ginkgo biloba on memory and cognitive function in patients with Alzheimer’s disease. Twenty-five studies published between 2010 and 2023 were analyzed, including randomized clinical trials, observational studies, and systematic reviews. The databases used included PubMed, Scopus, ScienceDirect, and SciELO, with keywords such as "Ginkgo biloba," "Alzheimer's disease," "cognitive function," and "neuroprotection." The results indicate that Ginkgo biloba possesses neuroprotective, antioxidant, and anti-inflammatory properties that contribute to the improvement of cognitive function in patients with Alzheimer's disease. Several studies demonstrated that Ginkgo biloba supplementation results in significant improvements in memory, attention, and executive function. Additionally, the combination of Ginkgo biloba with conventional treatments, such as cholinesterase inhibitors, proved to be particularly effective, enhancing therapeutic effects and offering a more holistic approach to disease management. Despite the promising results, the review highlights the need for more well-controlled, long-term clinical trials to standardize dosages and treatment protocols, as well as to confirm the safety and efficacy of Ginkgo biloba. The variability in study methods and administered dosages was a significant limitation, pointing to the need for further research in this area. In conclusion, Ginkgo biloba emerges as a valuable and promising therapeutic alternative in the management of Alzheimer's disease, offering improvements in cognitive function and quality of life for patients.


  • Genotoxic and Mutagenic Assessment of PT-31, a Molecule with Antipsychotic Potential

    by Cassiana Bigolin, Andriele Veiverberg, Gabriela Zimmermann Prado Rodrigues, Ana Letícia Hilario Garcia, Juliana Machado Kayser, Fernando Bertoldi, Marcelo Dutra Arbo, Marina Galdino Pitta, Ivan da Rocha Pitta, Günther Gehlen, et al.

    The PT-31 molecule, a potential antipsychotic, has demonstrated promising results when orally administrated to in vivo models. A recent study suggested the genotoxic and mutagenic potential of PT-31 after acute treatment by intraperitoneal route. This study aimed to evaluate PT-31 potential of inducing genotoxic or mutagenic damage after acute oral administration. For that, adult males and females Balb/C mice were treated acutely by oral administration with vehicle or PT-31 in three different doses (10, 20, and 40 mg kg-1). After 24 hours from PT-31 administration, animals were euthanized for performing the comet and micronucleus assays. None of the tested groups of PT-31 presented a significant increase in damage index and MN frequency. However, they presented the following tendency on damage index: females presented a tendency at 40 mg kg-1 and males at 20 mg kg-1. Regarding the MN assay, male mice at the highest dose of 40 mg kg-1 presented a tendency of increased MN frequency. Also, there was a significant increase in PCE/NCE ratio in male mice. Results suggest that the male mice group presented higher susceptibility to damage. The tendency of increased damage to DNA and MN frequency suggests that the molecule PT-31 may induce reparable damage to DNA, and these DNA strand repairs may have originated from the MN. However, significant genotoxic and mutagenic effects were not observed. This study reinforces the atypicality of the molecule as much as its safety by oral route administration.

  • New Trends in Biological Activities and Clinical Studies of Quinolinic Analogues: A Review

    by Sandra Elizabeth Barbosa da Silva, José Arion da Silva Moura, Tiago Rafael de Sousa Nunes, Ivan da Rocha Pitta, Marina Galdino da Rocha Pitta

    : The quinolinic ring, present in several molecules, possesses a great diversity of biological activities. Therefore, this ring is in the structural composition of several candidates of drugs in pre-clinical and clinical studies; thus, it is necessary to compile these results to facilitate the design of new drugs. For this reason, some of the activities of compounds are selected to examine in this re-view, such as antimalarial, antimicrobial, anticancer, anti-inflammatory, antidiabetic, anti-rheumatic, and antiviral activities. All publications of scientific articles chosen are dated between 2000 and 2020. In addition to presenting the structures of some natural and synthetic compounds with their activities, we have listed the clinical studies of phases III and IV on antimalarial drugs containing the quinoline nucleus and phase III clinical studies on hydroxychloroquine and chloroquine to assess their possible role in COVID-19. Finally, we have reviewed some of the mechanisms of action, as well as the side effects of some of the quinolinic derivatives.


  • Synthesis of novel thiazolidinic-phthalimide derivatives evaluated as new multi-target antiepileptic agents

    by Maria Cecilia V A de Oliveira, Douglas C F Viana, Anderson A Silva, Michelly C Pereira, Filipe S Duarte, Maira G R Pitta, Ivan R Pitta, Marina G R Pitta


  • Synthesis and biological activities of new phthalimide and thiazolidine derivatives

    by Flaviana A. Santos, Marcel L. Almeida, Vitor A. S. Silva, Douglas C. F. Viana, Michelly C. Pereira, André S. L. Lucena, Maira G. R. Pitta, Marina R. Galdino-Pitta, Moacyr J. B. de Melo Rêgo, Ivan da Rocha Pitta


  • Open Access

    Design, Synthesis and Biological Activities of New Phthalimide and Thiazolidine Derivatives

    by Flaviana A. Santos, Marcel L. Almeida, Vitor A. S. Silva, Douglas Carvalho Francisco Viana, Michelly C. Pereira, André S. L. Lucena, Marina Galdino da Rocha Pitta, Moacyr J. B. de Melo Rêgo, Ivan da Rocha Pitta

    The combination of pharmacophoric nuclei with different targets has been a strategy for the development of new drugs aimed at improving cancer treatment. A series of ten novel phthalimido-thiazolidine-2-4-dione derivatives were synthesized by two different synthetic routes. The compounds were tested and evaluated in vitro, through antineoplastic activities against cancer cells. Cell cycle analyzes and clonogenic assay were also performed. In addition to these tests, in silico predictions were performed. The synthesized FT-12 compound (9j) exhibited antiproliferative activity against Panc-1, Sk-mel-28 and PC-3 cells. FT-12 reduced the ability to form new clones, also caused irreversibility in cell cycle, inducing arrest in phase S. Besides, the compound (FT-12) caused necrosis and apoptosis. The results suggest that phthalimido-thiazolidine derivatives may be useful in cancer therapy, highlighting compound FT-12 (9j) as a promising candidate. More studies must be carried out to confirm the viability.

  • Open Access

    Análise do perfil de automedicação em tempos de COVID-19 no Brasil

    by Marina Galdino da Rocha Pitta, Luzilene Pereira de Lima, Jordy Silva de Carvalho, Diego Rodrigues Cravo Teixeira, Tiago Rafael de Sousa Nunes, José Arion da Silva Moura, Douglas Carvalho Francisco Viana, Ivan da Rocha Pitta

    Este manuscrito buscou a identificação do perfil brasileiro de automedicação na pandemia de COVID-19 e a reunião de informações sociodemográficas relacionadas ao uso da automedicação. Para tanto, foi investigado o conceito que os participantes depreendem sobre a automedicação, além de examinar qual o tipo de medicamento utilizado por quem se automedicou e seus efeitos colaterais. Foi realizada uma pesquisa no período de 03 de agosto a 30 de setembro de 2020. Os participantes deveriam apresentar uma idade mínima de 18 anos. As amostras estavam centradas em quem residia no Brasil. A pesquisa incluiu pessoas da população em geral. A coleta de dados se deu através de um questionário online, pois no referido período, as entrevistas presenciais deveriam ser evitadas devido ao contínuo lockdown. Coletaram-se dados de 1000 participantes para esta pesquisa. Os medicamentos que prevaleceram são da classe das vitaminas e, em segundo lugar, a Ivermectina. Destacou-se a indicação de automedicação por familiares. Os maiores índices de efeitos colaterais registrados foram cólicas intestinais e mal-estar. A prática da automedicação no Brasil mostrou-se preocupante no período de pandemia provocado pela COVID-19. Sendo assim, é importante que a população esteja atenta e seja criteriosa acerca das fontes de informações que discorrem sobre os medicamentos, evitando assim decisões precipitadas que podem ser mais prejudiciais.


  • Open Access

    Nanocarreadores aplicados ao tratamento do câncer de mama

    by Marina Galdino da Rocha Pitta, Rhuann Pontes dos Santos Silva, Guilherme Victor Santos Alves, Isabella Carla Barbosa Lima Angelo, Joana Martins de Souza, João Ricardo Caldas Pinheiro Pessôa, Jordy Silva de Carvalho, Maria Keyllane Vasconcelos de Miranda, Manuela Barbosa Rodrigues de Souza

    Objetivo: Avaliar as implicações da utilização dos nanocarreadores no tratamento do câncer de mama. Métodos: Revisão da literatura com base nas diretrizes contidas no Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA), utilizando as bases de dados: PubMed e Biblioteca Virtual em Saúde com os termos de busca: “nanopartículas” E “tratamento” E “câncer de mama”. Foram selecionados 19 artigos, escritos em inglês, que preencheram os critérios de inclusão. Resultados: Diante dos achados nos estudos selecionados, percebeu-se que os nanocarreadores apresentam baixa toxicidade a células saudáveis e as nanopartículas podem ser direcionadas para o local específico do tumor. Conclusão: este estudo permitiu compreender a eficácia das drogas utilizadas nos diferentes tipos de nanocarreadores para a redução das células tumorais com minimização da toxicidade e liberação do medicamento na região específica do tumor.